MYC and liver cancer: Additionally, as MYC drives mRNA translation of programmed death-ligand 1 (PD-L1) in KRAS-/MYC-driven liver cancer, which favors immune escape of the tumor, treatment of those mice with eFT508 or anti-PD-L1 therapy significantly prolonged the survival of the mice and reduced metastasis [151].